High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation

Cancer Research

Volumn 71, Issue 8, 2011, Pages 3018-3028

  Nassar, Taher ^a   Attili Qadri, Suha ^a   Harush Frenkel, Oshrat ^a   Farber, Shimon ^a   Lecht, Shimon ^a   Lazarovici, Philip ^a   Benita, Simon ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DOCETAXEL; GLYCOPROTEIN P; NANOCAPSULE; POLYGLACTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; DRUG UPTAKE; IN VITRO STUDY; INTESTINE CELL; LYMPHATIC SYSTEM; MALE; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPRAY DRYING;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CARCINOMA 256, WALKER; LACTIC ACID; MALE; NANOPARTICLES; POLYGLYCOLIC ACID; RATS; RATS, SPRAGUE-DAWLEY; TABLETS, ENTERIC-COATED; TAXOIDS; TISSUE DISTRIBUTION;

EID: 79954576965     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-3118     Document Type: Article

References (27)

1. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, et al. Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3- weekly docetaxel. J Clin Oncol 2005;20:8389-95.
2. Koolen SLW, Beijnen JH, Schellens JHM. Intravenous-to-oral switch in anticancer chemotherapy: A focus on docetaxel and paclitaxel. Clin Pharmacol Ther 2010;87:126-9.
3. Engels FK, Verweij J. Docetaxel administration schedule from fever to tears? A review of randomized studies. Eur J Cancer 2005;41:1117-26. (Pubitemid 40725569)
4. Park K. Nanovehicles for enhanced oral delivery of taxanes. J Control Release 2009;140:77-8.
5. Schellens JH, Malingré MM, Kruijtzer CM, Bardelmeijer HA, van Tellingen O, Schinkel AH, et al. Modulation of oral bioavailability of anticancer drugs: From mouse to man. Eur J Pharm Sci 2000;12:103-10.
6. van Herwaarden AE, Wagenaar E, Van Der Kruijssen CM, van Waterschoot RA, Smit JW, Song JY, et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 2007;117:3583-92. (Pubitemid 350097013)
7. van Waterschoot RA, Lagas JS, Wagenaar E, Van Der Kruijssen CM, van Herwaarden AE, Song JY, et al. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 2009; 69:8996-9002.
8. Malingré MM, Richel DJ, Beijnen JH, Rosing H, Koopman FJ, Ten Bokkel Huinink WW, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001;19: 1160-6. (Pubitemid 32176294)
9. Yang S, Gursoy RN, Lambert G, Benita S. Enhanced oral absorption of paclitaxel in a novel self-microemulsifying drug delivery system with or without concomitant use of P-glycoprotein inhibitors. Pharm Res 2004;21:261-70. (Pubitemid 38221971)
10. Breedveld P, Beijnen JH, Schellens JH. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. Trends Pharmacol Sci 2006; 27:17-24. (Pubitemid 43063120)
11. Bardelmeijer HA, Ouwehand M, Buckle T, Huisman MT, Schellens JHM, Beijnen JH, et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002;62:6158-64. (Pubitemid 35244466)
12. Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, et al. HIV-1 Protease inhibitor, ritonavir: A potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004;64:7426-31. (Pubitemid 39372084)
13. Oostendorp RL, Huitema A, Rosing H, Jansen RS, ter Heine R, Keessen MR, et al. Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors. Clin Cancer Res 2009;15:4228-33.
14. Koolen SL, Oostendorp RL, Beijnen JH, Schellens JH, Huitema AD. Population pharmacokinetics of intravenously and orally administered docetaxelwith or without co-administration of ritonavir in patients with advanced cancer. Br J Clin Pharmacol 2010;69:465-74.
15. Wang W, Ke S, Kwon S, Yallampalli S, Cameron AG, Adams KE, et al. A new optical and nuclear dual-labeled imaging agent targeting interleukin 11 receptor alpha-chain. Bioconjug Chem 2007;18:397-402. (Pubitemid 46493510)
16. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, et al. Comparative preclinical and clinical pharmacokinetics of a cremophor- free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin Cancer Res 2005;11: 4136-43. (Pubitemid 40791578)
17. Kivisto KT, Niemi M, Fromm MF. Functional interaction of intestinal CYP3A4 and P-glycoprotein. Fundam Clin Pharmacol 2004;18:621-6. (Pubitemid 39564261)
18. Benet LZ. The drug transporter-metabolism alliance: Uncovering and defining the interplay. Mol Pharm 2009;6:1631-43.
19. Baker SD, Sparreboom A, Verweij J. Clinical pharmacokinetics of docetaxel: Recent developments. Clin Pharmacokinet 2006;45:235-52. (Pubitemid 43327491)
20. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of Taxotere and its derivatives: Enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998;8:391-401. (Pubitemid 28475303)
21. Malingré MM, Ten Bokkel Huinink WW, Mackay M, Schellens JH, Beijnen JH. Pharmacokinetics of oral cyclosporin a when co-administered to enhance the absorption of orally administered docetaxel. Eur J Clin Pharmacol 2001;57:305-7. (Pubitemid 32703937)
22. Yin YM, Cui FD, Mu CF, Choi M-K, Kim JS, Chung S-J, et al. Docetaxel microemulsion for enhanced oral bioavailability: Preparation and in vivo evaluation. J Control Release 2009;140:86-94.
23. Feng SS, Mei L, Anitha P, Gan CW, Zhou W. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Biomaterials 2009;30:3297-306.
24. Santos Magalhaes NS, Fessi H, Puisieux F, Benita S, Seiller M. An invitro release kinetic examination and comparative evaluation between submicron emulsions and polylactic acid nanocapsules of clofibride. J Microencapsulation 1995;12:195-205.
25. Engels FK, Mathot RAA, Verweij J. Alternative drug formulations of docetaxel: A review. Anticancer Drugs 2007;18:95-102.
26. Yan C, Gu J, Guo Y, Chen D. In vivo biodistribution for tumor targeting of 5-fluorouracil (5-FU) loaded N-succinyl-chitosan (Suc-Chi) nanoparticles. Yakugaku Zasshi 2010;130:801-4.
27. Harush-Frenkel O, Altschuler Y, Benita S. Nanoparticle-cell interactions- drug delivery implication. Crit Rev Ther Drug Carrier Syst 2008;25:485-544.